Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1α-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea

British Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 33-39

  Makishima, M ^a   Okabe Kado, J ^a   Honma, Y ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Hydroxyurea; Leukaemia; Vitamin D2; Vitamin D3; Vitamin D4; Vitamin D7

Indexed keywords

ALFACALCIDOL; CAMPTOTHECIN; CD11B ANTIGEN; CD14 ANTIGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYDROXYUREA;

ARTICLE; CELL DIFFERENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

EID: 0031985235     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.6     Document Type: Article

References (35)

1. 3 Proc Natl Acad Sci USA 78: 4990-4994
2. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837
3. Athens JW (1993) Chronic myeloid leukaemia. In Wintrobe's Clinical Hematology, Lee GR, Bithell TC, Foerster J, Athens JW and Lukens JN. (eds). pp. 1969-1998. Lea & Febger: Philadelphia
4. Berenbaum MC (1989) What is synergy? Pharmacol Rev 41: 93-141
5. Bolton BH, Woods LA, Kaung DT and Lawton RL (1965) A simple method of colorimetric analysis for hydroxyurea (NSV-32065). Cancer Treat Rep 46: 1-5
6. Bodner AJ, Ting RC and Gallo RC (1981) Induction of differentiation of human promyelocytic leukemia cells (HL-60) by nucleosides and methotrexate. J Natl Cancer Inst 67: 1025-1030
7. Calabresi P, Chabner BA (1996) Chemotherapy of neoplastic diseases. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edn, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG. (eds), pp. 1225-1287. McGraw-Hill: New York
8. Davidson JD and Winter TS (1963) A method of analyzing for hydroxyurea in biological fluids. Cancer Chemother Rep 27: 97-110
9. Degos L, Dombret H, Chomienne C, Daniel M-T, Micléa J-M, Chastang C, Castaigne S and Fenaux P (1995) All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 85: 2643-2653
10. Fenaux P, Vanhaesbroucke C, Estienne MH, Preud'Homme C, Pagniez D, Facon T, Millot F and Bauters F (1990) Acute monocytic leukaemia in adults: treatment and prognosis in 99 cases. Br J Haematol 75: 41-48
11. 3 on calcium homeostasis in postmenopausal osteopenic women. J Bone Miner Res 9: 607-614
12. Goldman JM (1994) A special report: bone marrow transplants using volunteer donors recommendations and requirements for a standardized practice throughout the world 1994 update. Blood 84: 2833-2839
13. 3. Science 190: 576-578
14. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80: 201-204
15. Housset M, Daniel MT and Degos L (1982) Small doses of Ara-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells? Br J Haematol 51: 125-129
16. Ishiguro K and Sartorelli AC (1985) Enhancement of the differentiation-inducing properties of 6-thioguanine by hypoxanthine and its nucleosides in HL-60 promyelocytic leukemia cells. Cancer Res 45: 91-95
17. 3 in normal human monocytes. J Biol Chem 270: 22160-22166
18. 3: in vivo and in vitro effects on human preleukemic and leukemic cells. Cancer Treat Rep 69: 1399-1407
19. Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F and Berger R (1991) NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood 77: 1080-1086
20. 3 cooperatively inhibit proliferation and induce differentiation of human myeloid leukemia cells. Leuk Res 20: 781-789
21. 3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an α-tocopherol ester of all-trans retinoic acid. Blood 87: 3384-3394
22. 3 induces differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 102: 937-943
23. 3 by human monocytic leukemia cells. FEBS Lett 309: 399-401
24. Overton WR (1988) Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry 9: 619-626
25. 3 analogs: effect on leukemic clonal growth and differentiation, and on serum calcium levels. Leuk Res 19: 65-72
26. Sato F, Okamoto Y, Ouchi Y, Kaneki M, Nakamura T, Ikekawa N and Orimo H (1991) Biological activity of 1α,25-dihydroxyvitamin D derivatives - 24-epi-1α,25-dihydroxyvitamin D-2 and 1α,25-dihydroxyvitamin D-7. Biochim Biophys Acta 1091: 188-192
27. Schiffer CA (1996) Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 88: 3675-3685
28. 3 in the rat. Proc Soc Exp Biol Med 178: 432-436
29. Steel GG and Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85-91
30. 3 of cytotoxicity to HL-60 cells produced by cytarabine and hydroxyurea. J Natl Cancer Inst 76: 641-648
31. Tachibana Y and Tsuji M (1992) Synthetic studies on active forms of vitamin D and their analogs. In Studies in Natural Products Chemistry, Vol. 11, Rahman AU. (ed.), pp. 379-408. Elsevier: Amsterdam
32. Tanaka H, Abe E, Miyaura C, Kuribayashi T, Konno K, Nishii Y and Suda T (1982) 1α,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). The presence of a cytosol receptor and induction of differentiation. Biochem J 204: 713-719
33. 3. Cancer Res 54: 4508-4515
34. Venditti A, Stasi R, Del Poeta G, Buccisano F, Aronica G, Bruno A, Pisani F, Caravita T, Masi M, Tribalto M, Simone MD, Avvisati G, Amadori S and Papa G (1995) All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. Leukemia 9: 1121-1125
35. Yen A, Freeman L and Fishbaugh J (1987) Hydroxyurea induces precommitment during retinoic induced HL-60 terminal myeloid differentiation: possible involvement of gene amplification. Leuk Res 11: 63-71